From December 31, 2023 to March 30, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 997,406 shares, representing 1.95% for $75 million under the buyback announced on August 10, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
83.18 USD | +0.25% |
|
-2.71% | -2.72% |
Jun. 18 | Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device | CI |
Jun. 12 | Haemonetics Shares Rise After Upgrade From Needham | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.72% | 4.23B | |
-4.92% | 182B | |
-3.70% | 103B | |
-5.29% | 66.94B | |
+10.99% | 46.73B | |
-7.70% | 45.14B | |
+6.64% | 41.57B | |
+15.96% | 30.48B | |
+14.08% | 24.26B | |
-6.63% | 23.58B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Tranche Update on Haemonetics Corporation's Equity Buyback Plan announced on August 10, 2022.